Morine Yuji, Shimada Mitsuo, Ikemoto Tetsuya, Arakawa Yusuke, Iwahashi Shuichi, Saito Y U, Yamada Shinichiro, Imura Satoru
Department of Surgery, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima, Japan
Department of Surgery, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima, Japan.
Anticancer Res. 2017 Nov;37(11):6421-6428. doi: 10.21873/anticanres.12096.
BACKGROUND/AIM: The aim of this retrospective study was to clarify the effectiveness of chemotherapy with gemcitabine combined with low-dose 5-fluorouracil and cisplatin (GFP) for advanced biliary carcinoma after hepatectomy.
Sixty-two patients had biliary carcinoma with lymph node metastasis, intrahepatic metastasis or positive surgical margins, including intrahepatic cholangiocarcinoma (IHC, n=25), hilar cholangiocarcinoma (HC, n=14), and gallbladder cancer (GBC, n=23). Twenty-eight patients (IHC; n=9, HC; n=8, GBC; n=11) received adjuvant GFP chemotherapy.
We found no significant difference in clinicopathological factors in patients treated with or without adjuvant GFP chemotherapy. Overall, survival in the adjuvant GFP group was significantly better than that in the non-adjuvant GFP group (3-year survival: 61.9% vs. 8.8%, p<0.001), as was relapse-free survival.
Adjuvant GFP chemotherapy after hepatectomy may be a promising option for improving surgical outcomes in patients with advanced biliary carcinoma.
背景/目的：本回顾性研究旨在阐明吉西他滨联合低剂量5-氟尿嘧啶和顺铂（GFP）化疗对肝切除术后晚期胆管癌的疗效。
62例胆管癌患者伴有淋巴结转移、肝内转移或手术切缘阳性，包括肝内胆管癌（IHC，n = 25）、肝门胆管癌（HC，n = 14）和胆囊癌（GBC，n = 23）。28例患者（IHC；n = 9，HC；n = 8，GBC；n = 11）接受了辅助GFP化疗。
我们发现接受或未接受辅助GFP化疗的患者在临床病理因素上无显著差异。总体而言，辅助GFP组的生存率显著高于非辅助GFP组（3年生存率：61.9%对8.8%，p<0.001），无复发生存率也是如此。
肝切除术后辅助GFP化疗可能是改善晚期胆管癌患者手术结局的一个有前景的选择。
